The FDA originally approved Cyltezo in 2017. Now, pharmacists can substitute it for AbbVie’s Humira without needing a prescriber to change the prescription.
Cyltezo, a tumor necrosis factor blocker, is approved to treat several diseases, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis and plaque psoriasis.
Cyltezo is the second interchangeable biosimilar product approved by the agency.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
